SCHEMBL9904280

SCHEMBL9904280

COc1cc(-c2cn(S(=O)(=O)c3ccc(C)cc3)c3ccc(-c4c(F)cccc4F)cc23)nc(N2CCC(NC(=O)O)CC2)n1

nearest known ligand 0.39

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ PIM1 P11309 1/20 0.39
▸ PIM2 Q9P1W9 1/20 0.39
▸ HTR6 P50406 9/20 0.36
▸ ALDH1A1 P00352 2/20 0.36
▸ HPGD P15428 1/20 0.36
▸ TSHR P16473 1/20 0.36
▸ HSD17B10 Q99714 1/20 0.36
▸ FLT3 P36888 1/20 0.36
▸ L3MBTL1 Q9Y468 1/20 0.35
▸ MEN1 O00255 3/20 0.35
▸ KMT2A Q03164 3/20 0.35
▸ DRD2 P14416 2/20 0.35
▸ HTR2A P28223 2/20 0.35
▸ ALOX5 P09917 1/20 0.35
▸ KIT P10721 1/20 0.35
▸ KCNH2 Q12809 1/20 0.35
▸ HTR7 P34969 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9904527 0.81 TYK2 (0.43) PIM1PIM2ALDH1A1HPGDTSHR
SCHEMBL9904528 0.77 PIK3CD (0.39) PIM1PIM2HTR6FLT3
SCHEMBL9904525 0.77 PIK3CD (0.39) PIM1PIM2HTR6FLT3
SCHEMBL9904681 0.73 CKS1B (0.40) PIM1PIM2
SCHEMBL9942513 0.72 TYK2 (0.40) PIM1
SCHEMBL12615970 0.70 PIM1 (0.51) PIM1PIM2HTR6FLT3L3MBTL1
SCHEMBL15446191 0.69 PIM1 (0.43) PIM1PIM2HTR6ALDH1A1HPGD
SCHEMBL9904437 0.69 CKS1B (0.37) PIM1PIM2FLT3MEN1KMT2A
SCHEMBL9901268 0.68 TYK2 (0.42) PIM1PIM2HTR6ALOX5
SCHEMBL9901269 0.68 TYK2 (0.42) PIM1PIM2HTR6ALOX5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9090593-B2 Bicyclic compounds as Pim inhibitors AMGEN INC. (US) 2015-07-28 — — US disclosed
EP-2796456-A1 Bicyclic compounds as Pim inhibitors Amgen Inc. (US) 2014-10-29 — — EP disclosed
US-20140031360-A1 BICYCLIC COMPOUNDS AS PIM INHIBITORS AMGEN INC. (US) 2014-01-30 — — US disclosed
EP-2649065-A1 BICYCLIC COMPOUNDS AS PIM INHIBITORS Amgen Inc. (US) 2013-10-16 — — EP disclosed
WO-2012078777-A1 BICYCLIC COMPOUNDS AS PIM INHIBITORS AMGEN INC. (US) 2012-06-14 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140031360-A1 BICYCLIC COMPOUNDS AS PIM INHIBITORS PIM1, PIM2, PIM3 PIM1 1/4885PIM2 2/4885HTR6 4372/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback